An investigation by NBC News sheds light on the inconsistencies in how states monitor issues related to peptides. The investigation reveals a disjointed system of oversight policies across different states.
The Case of Sarah Moran
Sarah Moran encountered significant side effects after taking a popular peptide dose in February. She reported experiencing a rapid heartbeat upon standing and persistent dizziness lasting for several days.
Current Oversight Challenges
Many experts believe there is inadequate regulation in place. They assert that allowing compounding pharmacies to produce certain peptides will not provide the necessary oversight.
Lack of Uniform Policies
Various states have adopted a patchwork approach to monitoring these substances. This lack of uniform policies poses risks to individuals like Sarah who may face adverse effects without sufficient regulatory protection.
Federal Borrowing Limits and Their Impact on Medical Education 
The Real Lessons from Global Healthcare Systems 
Inversion Tables for Chronic Pain Relief 
Medications May Leave Long-Lasting Imprints on Gut Bacteria 
Understanding Measles Outbreaks in 2026 
Democratizing Parenthood: Making Family Building Accessible